Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
ORPHELIA, Ethypharm Sign Kigabeq® Licensing Deal for China
Details : Orphelia has granted Ethypharm exclusive rights under a license agreement to commercialize Kigabeq (vigabatrin) in China. Kigabeq is indicated as a first-line treatment for infantile spasms.
Product Name : Kigabeq
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 19, 2021
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : ClinSearch
Deal Size : Inapplicable
Deal Type : Inapplicable
TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide
Details : Temozolomide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 30, 2020
Lead Product(s) : Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : ClinSearch
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Temozolomide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules
Details : Temozolomide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 13, 2020
Lead Product(s) : Temozolomide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VGB
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VGB is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 13, 2020
Lead Product(s) : VGB
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : INSERM | Hospices Civils de Lyon | National Research Agency, France
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vigabatrin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Spasms, Infantile.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2014
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : INSERM | Hospices Civils de Lyon | National Research Agency, France
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
